Pharos iBio (A388870) Stock Overview
Engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A388870 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Pharos iBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,450.00 |
| 52 Week High | ₩12,120.00 |
| 52 Week Low | ₩4,630.00 |
| Beta | -0.24 |
| 1 Month Change | -16.52% |
| 3 Month Change | -10.85% |
| 1 Year Change | 34.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.25% |
Recent News & Updates
We're Keeping An Eye On Pharos iBio's (KOSDAQ:388870) Cash Burn Rate
Aug 22
Will Pharos iBio (KOSDAQ:388870) Spend Its Cash Wisely?
Apr 14Recent updates
We're Keeping An Eye On Pharos iBio's (KOSDAQ:388870) Cash Burn Rate
Aug 22Will Pharos iBio (KOSDAQ:388870) Spend Its Cash Wisely?
Apr 14Here's Why We're Not Too Worried About Pharos iBio's (KOSDAQ:388870) Cash Burn Situation
Dec 16We Think Pharos iBio (KOSDAQ:388870) Can Easily Afford To Drive Business Growth
Mar 07Shareholder Returns
| A388870 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 8.6% | 4.7% | 3.9% |
| 1Y | 34.8% | 41.8% | 138.3% |
Return vs Industry: A388870 underperformed the KR Biotechs industry which returned 41.8% over the past year.
Return vs Market: A388870 underperformed the KR Market which returned 138.3% over the past year.
Price Volatility
| A388870 volatility | |
|---|---|
| A388870 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.3% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A388870 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A388870's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Jeong Hyeok Yoon | www.pharosibio.com |
Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Pharos iBio Co., Ltd. Fundamentals Summary
| A388870 fundamental statistics | |
|---|---|
| Market cap | ₩122.34b |
| Earnings (TTM) | -₩10.76b |
| Revenue (TTM) | n/a |
Is A388870 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A388870 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩20.32m |
| Gross Profit | -₩20.32m |
| Other Expenses | ₩10.74b |
| Earnings | -₩10.76b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -830.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 55.5% |
How did A388870 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 00:40 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharos iBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.